首页> 外文期刊>Southern African journal of HIV medicine >False rifampicin resistant results using Xpert MTB/RIF on urine samples in hospitalised HIV-infected patients
【24h】

False rifampicin resistant results using Xpert MTB/RIF on urine samples in hospitalised HIV-infected patients

机译:使用Xpert MTB / RIF在住院HIV感染患者中使用Xpert MTB / RIF的假利福平耐药结果

获取原文
           

摘要

A small proportion of false rifampicin resistant results have previously been reported using GeneXpert MTB/RIF version G4 on sputum samples; however, this has not been investigated for urine samples in HIV-associated tuberculosis (TB). We sought to determine the proportion of false rifampicin resistant results using Xpert MTB/RIF version G4 on urine samples among HIV-infected inpatients investigated for TB. Hospitalised HIV-infected patients undergoing systematic TB testing from two cohorts in Cape Town, South Africa, were enrolled. All patients with ≥1 urine Xpert result available were included. Rifampicin resistant urine Xpert results were classified into three mutually exclusive groups: (1) true rifampicin resistance, (2) false rifampicin resistance or (3) unknown after review of available microbiologic and clinical data. Overall, 1171 patients were included, from whom a total of 1704 urine Xpert results were available on unconcentrated and/or concentrated urine samples. There were 416 samples positive for TB (24.4% [95% CI 22.4-26.5]), of which 43/413 (10.4% [95% CI 7.6-13.8]) were rifampicin resistant (after excluding three results that were falsely positive due to contamination). Of 43 rifampicin resistant Xpert results (among 40 patients), 30 were classified as true resistance, 11 as false resistance and 2 could not be classified. Excluding unclassifiable results, 30/41 results were confirmed as true-positive urine Xpert rifampicin resistance (positive predictive value: 73.2% [95% CI 57.1-85.8]). Urine Xpert testing showed a high proportion of false rifampicin resistance results. Urine Xpert rifampicin resistant results should be interpreted cautiously and confirmed when possible.
机译:使用痰样品上的Genexpert MTB / RIF版G4先前据报道了一小部分假利福平耐药结果;然而,这尚未研究艾滋病毒相关结核病(TB)中的尿液样本。我们试图使用Xpert MTB / RIF Version G4对TB研究的尿液样本上的尿液样本上的假利福平抗性结果的比例。住院患病患者接受了南非开普敦开普敦的两个队列系统的艾滋病毒感染患者。所有≥1尿XPERT结果的患者都包括可用。利福平抗性尿XPERT结果分为三个相互排斥的群体:(1)真正的利福平抗性,(2)在可用的微生物学和临床数据审查后未知的假利福平抗性或(3)。总体而言,包括1171名患者,共有1704株尿XPERT结果可用于非浓度和/或浓缩的尿液样本。 Tb的416个样品(24.4%[95%CI 22.4-26.5]),其中43/413(10.4%[95%CI 7.6-13.8])是利福平抗性(除了三种结果时,错误阳性为主污染)。在43只利福平抗性Xpert结果(40名患者中),30分为真正的抵抗,11作为假抵抗,2个不能分类。不包括未划分的结果,30/41个结果被证实为真正阳性尿Xpert利福平抗性(阳性预测值:73.2%[95%CI 57.1-85.8])。尿XPERT测试显示出高比例的假利福平抗性结果。尿Xpert利福平抗性结果应在可能的情况下谨慎解释并确认。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号